Advanced search
Publication Cover
Leukemia & Lymphoma Volume 62, 2021 - Issue 14
Submit an article Journal homepage
484
Views
13
CrossRef citations to date
0
Altmetric
Original Articles

COVID-19 among patients with hematological malignancies: a national Israeli retrospective analysis with special emphasis on treatment and outcome

Ilana Levya Hematology Unit, Bnai Zion Medical Center, Haifa, Israel;b Faculty of Medicine, Technion- Israel Institute of Technology, Haifa, IsraelCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-8923-1467
ORCID Icon,
Avital Lavib Faculty of Medicine, Technion- Israel Institute of Technology, Haifa, Israel
,
Eran Zimranc Hematology Department, Hadassah Hospital, Jerusalem, Israel;d Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel
,
Sigal Grisariuc Hematology Department, Hadassah Hospital, Jerusalem, Israel;d Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel
,
Shlomzion Aumannc Hematology Department, Hadassah Hospital, Jerusalem, Israel;d Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel
,
Gilad Itchakie Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center, Petah Tikva, Israel;f Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, IsraelORCID Iconhttps://orcid.org/0000-0002-9064-8139
ORCID Icon,
Tamar Bergere Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center, Petah Tikva, Israel;f Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
,
Pia Raananie Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center, Petah Tikva, Israel;f Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
,
Reut Harelb Faculty of Medicine, Technion- Israel Institute of Technology, Haifa, Israel;g Hematology Unit, HaEmek Medical Center, Afula, Israel
,
Ariel Avivb Faculty of Medicine, Technion- Israel Institute of Technology, Haifa, Israel;g Hematology Unit, HaEmek Medical Center, Afula, Israel
,
Noa Lavib Faculty of Medicine, Technion- Israel Institute of Technology, Haifa, Israel;h Hematology Institute, Rambam Medical Center, Haifa, Israel
,
Tsila Zuckermanb Faculty of Medicine, Technion- Israel Institute of Technology, Haifa, Israel;h Hematology Institute, Rambam Medical Center, Haifa, IsraelORCID Iconhttps://orcid.org/0000-0002-6204-977X
ORCID Icon,
Lev Shvideld Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel;i Hematology Unit, Kaplan Medical Center, Rehovot, Israel
,
Osnat Jarchowskyf Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel;j Hematology Department, Meir Medical Center, Kfar Saba, Israel
,
Martin Ellisf Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel;j Hematology Department, Meir Medical Center, Kfar Saba, Israel
,
Katrin Herzog Tzarfatif Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel;k Hematology Department, Shamir Medical Center, Zerifin, Israel
,
Maya Koren-Michowitzf Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel;k Hematology Department, Shamir Medical Center, Zerifin, IsraelORCID Iconhttps://orcid.org/0000-0002-7223-328X
ORCID Icon,
Yehonatan Sherfl Hematology Department, Soroka Medical Center, Beer-Sheva, Israel;m Faculty of Medicine, Ben-Gurion University of the Negev, Beer-Sheva, IsraelORCID Iconhttps://orcid.org/0000-0003-0300-1802
ORCID Icon,
Itai Levil Hematology Department, Soroka Medical Center, Beer-Sheva, Israel;m Faculty of Medicine, Ben-Gurion University of the Negev, Beer-Sheva, Israel
,
Orit Soferb Faculty of Medicine, Technion- Israel Institute of Technology, Haifa, Israel;n Hematology Unit, Hillel Yaffe Medical Center, Hadera, Israel
,
Ofer Shpilbergf Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel;o Hematology Unit, Assuta Ramat Hahayal Medical Center, Tel Aviv, Israel
,
Nagib Dallyp Hematology Unit, Ziv Medical Center, Safed, Israel;q Faculty of Medicine, Bar Ilan Unifersity, Safed, Israel
,
Celia Suriuq Faculty of Medicine, Bar Ilan Unifersity, Safed, Israel;r Hematology Institute, Western Galilee Hospital, Nahariya, Israel
,
Andrei Braesterq Faculty of Medicine, Bar Ilan Unifersity, Safed, Israel;r Hematology Institute, Western Galilee Hospital, Nahariya, Israel
,
Sharon Ben Barouchm Faculty of Medicine, Ben-Gurion University of the Negev, Beer-Sheva, Israel;s Hematology Unit, Assuta Ashdod Medical Center, Ashdod, Israel
,
Merav Leibam Faculty of Medicine, Ben-Gurion University of the Negev, Beer-Sheva, Israel;s Hematology Unit, Assuta Ashdod Medical Center, Ashdod, Israel
,
Daniela Goldsteinf Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel;t Hematology Unit, Wolfson Medical Center, Holon, Israel
,
Nadav Saridf Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel;t Hematology Unit, Wolfson Medical Center, Holon, Israel
,
Shay Yeganehq Faculty of Medicine, Bar Ilan Unifersity, Safed, Israel;u Hematology Unit, Baruch Padeh Medical Center, Poriyah, Israel
,
Jabour Hallouna Hematology Unit, Bnai Zion Medical Center, Haifa, Israel
,
Moshe Mittelmanf Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel;v Internal Medicine A Department, Sourasky Medical Center, Tel Aviv, Israel
&
Tamar Tadmora Hematology Unit, Bnai Zion Medical Center, Haifa, Israel;b Faculty of Medicine, Technion- Israel Institute of Technology, Haifa, Israel
 show all
Pages 3384-3393 | Received 28 Apr 2021, Accepted 01 Aug 2021, Published online: 18 Aug 2021

References

  • Lake MA. What we know so far: COVID-19 current clinical knowledge and research. Clin Med (Lond). 2020;20(2):124–127.
  • Yigenoglu TN, Ata N, Altuntas F, et al. The outcome of COVID-19 in patients with hematological malignancy. J Med Virol. 2021;93(2):1099–1104.
  • Piñana JL, Martino R, García-García I, et al. Risk factors and outcome of COVID-19 in patients with hematological malignancies. Exp Hematol Oncol. 2020;9(1):1–16.
  • Passamonti F, Cattaneo C, Arcaini L, et al. Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study. Lancet Haematol. 2020;7(10):e737–e745.
  • Vijenthira A, Gong IY, Fox TA, et al. Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and Meta-analysis of 3377 patients. Blood. 2020;136(25):2881–2892.
  • Hu Y, Wang L, Cui Q, et al. COVID-19 in hematologic malignancies: big challenges. Clin Hematol Int. 2020;2(4):173–175.
  • Galimberti S, Petrini M, Baratè C, et al. Tyrosine kinase inhibitors play an antiviral action in patients affected by chronic myeloid leukemia: a possible model supporting their use in the fight against SARS-CoV-2. Front Oncol. 2020;10:1428–1429.
  • Lin AY, Cuttica MJ, Ison MG, et al. Ibrutinib for chronic lymphocytic leukemia in the setting of respiratory failure from severe COVID‐19 infection: Case report and literature review. eJHaem. 2020;1(2):596–600.
  • Molina-Cerrillo J, Marquet-Palomanes J, Alonso-Gordoa T, et al. May ibrutinib have activity in respiratory complications by SARS-CoV-2? Clinical experience in a patient with chronic lymphocytic leukemia. Healthcare. 2021;9(1):78.
  • Garciá-Suárez J, De La Cruz J, Cedillo Á, et al. Impact of hematologic malignancy and type of cancer therapy on COVID-19 severity and mortality: Lessons from a large population-based registry study. J Hematol Oncol. 2020;13(1):133–112.
  • Jeyaraman P, Agrawal N, Bhargava R, et al. Convalescent plasma therapy for severe Covid-19 in patients with hematological malignancies. Transfus Apher Sci. 2021;60(3):103075.
  • Thompson MA, Henderson JP, Shah PK, et al. Convalescent plasma and improved survival in patients with hematologic malignancies and COVID-19. medRxiv. 2020;1–13. Available from: https://doi.org/https://doi.org/10.1101/2021.02.05.21250953
  • Rochwerg B, Siemieniuk RA, Agoritsas T, et al. A living WHO guideline on drugs for covid-19. BMJ. 2020;370:m3379.
  • Israeli Ministry of Health. COVID-19 datashboard. [cited 2021 March 20]. Available from: https://datadashboard.health.gov.il/COVID-19/general?utm_source=go.gov.il&utm_medium=referral
  • Saban M, Myers V, Wilf-Miron R. Coping with the COVID-19 pandemic - the role of leadership in the Arab ethnic minority in Israel. Int J Equity Health. 2020;19(1):154–156.
  • Li J, Smith A, Crouch S, et al. Estimating the prevalence of hematological malignancies and precursor conditions using data from Haematological Malignancy Research Network (HMRN). Cancer Causes Control. 2016;27(8):1019–1026.
  • Mizrahi B, Shilo S, Rossman H, et al. Longitudinal symptom dynamics of COVID-19 infection. Nat Commun. 2020;11(1):6208–6210.
  • World Health Organization. (2021). Therapeutics and COVID-19: living guideline, 31 March 2021. World Health Organization. https://apps.who.int/iris/handle/10665/340374.
  • Malard F, Genthon A, Brissot E, et al. COVID-19 outcomes in patients with hematologic disease. Bone Marrow Transplant. 2020;55(11):2180–2184.
  • Wood WA, Neuberg DS, Colton Thompson J, et al. Outcomes of patients with hematologic malignancies and COVID-19: a report from the ASH Research Collaborative Data Hub. Blood Adv. 2020;4(23):5966–5975.
  • He W, Chen L, Chen L, et al. COVID-19 in persons with haematological cancers. Leukemia. 2020;34(6):1637–1645.
  • Lee LYW, Cazier JB, Angelis V, et al. COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study. Lancet. 2020;395(10241):1919–1926.
  • Scarfò L, Chatzikonstantinou T, Rigolin GM, et al. COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus. Leukemia. 2020;34(9):2354–2363.
  • Langerbeins P, Eichhorst B. Immune dysfunction in patients with chronic lymphocytic leukemia and challenges during COVID-19 pandemic. Acta Haematol. 2021;1–11. doi: https://doi.org/10.1159/000514071.
  • Levy I, Sharf G, Norman S, et al. The impact of COVID-19 on patients with hematological malignancies: the mixed-method analysis of an Israeli national survey. Support Care Cancer. 2021. doi: https://doi.org/10.1007/s00520-021-06324-4.
  • Rivera DR, Peters S, Panagiotou OA, et al. Utilization of covid-19 treatments and clinical outcomes among patients with cancer: a covid-19 and cancer consortium (CCC19) cohort study. Cancer Discov. 2020;10(10):1514–1527.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.